Humana Inc (NYSE:HUM) Sees Significant Increase in Short Interest

Humana Inc (NYSE:HUM) saw a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 2,459,200 shares, a growth of 24.1% from the April 30th total of 1,981,200 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.8% of the shares of the company are short sold.

Hedge funds have recently modified their holdings of the stock. Norges Bank acquired a new stake in Humana in the fourth quarter worth approximately $402,117,000. Millennium Management LLC lifted its position in Humana by 254.8% in the fourth quarter. Millennium Management LLC now owns 503,066 shares of the insurance provider’s stock worth $144,118,000 after purchasing an additional 361,263 shares during the period. Ceredex Value Advisors LLC lifted its position in Humana by 31.8% in the first quarter. Ceredex Value Advisors LLC now owns 957,094 shares of the insurance provider’s stock worth $255,111,000 after purchasing an additional 230,671 shares during the period. BlackRock Inc. lifted its position in Humana by 1.6% in the first quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock worth $3,242,553,000 after purchasing an additional 186,997 shares during the period. Finally, Calamos Advisors LLC lifted its position in Humana by 114.4% in the first quarter. Calamos Advisors LLC now owns 306,086 shares of the insurance provider’s stock worth $81,419,000 after purchasing an additional 163,339 shares during the period. 92.61% of the stock is owned by institutional investors and hedge funds.

HUM stock traded up $2.25 on Thursday, reaching $259.04. The company’s stock had a trading volume of 34,576 shares, compared to its average volume of 1,364,949. Humana has a 52 week low of $225.65 and a 52 week high of $355.88. The firm has a market capitalization of $34.83 billion, a price-to-earnings ratio of 17.67, a price-to-earnings-growth ratio of 1.06 and a beta of 0.85. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.30 by $0.18. Humana had a return on equity of 20.77% and a net margin of 2.99%. The business had revenue of $16.11 billion during the quarter, compared to analyst estimates of $15.67 billion. During the same period in the prior year, the company posted $3.36 EPS. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. On average, equities analysts anticipate that Humana will post 17.48 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s dividend payout ratio (DPR) is 15.12%.

Several equities analysts have recently commented on the company. Oppenheimer lowered their target price on Humana from $373.00 to $350.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. Credit Suisse Group lowered their target price on Humana from $352.00 to $315.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. Citigroup lowered their target price on Humana from $362.00 to $302.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. SunTrust Banks lowered their target price on Humana to $300.00 in a report on Thursday, May 2nd. Finally, UBS Group assumed coverage on Humana in a report on Tuesday, April 23rd. They set a “neutral” rating and a $266.00 target price for the company. Two analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $337.26.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: Percentage Decliners

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.